Kenalog, ampoules 40mg/ml, 1ml, 5pcs

Composition

>1 ml of suspension for injection contains: triamcinolone acetonide 40 mg and benzyl alcohol 9.9 mg in an isotonic sodium chloride solution.

Pharmacological action

Pharmaceutical Group:

glucocorticosteroid.

Pharmaceutical action:

 Kenalog – GCS. Inhibits the functions of leukocytes and tissue macrophages. Restricts the migration of white blood cells to the area of inflammation. Interferes with the ability of macrophages to phagocytosis, as well as to form interleukin-1.

It helps to stabilize lysosomal membranes, thereby reducing the concentration of proteolytic enzymes in the area of inflammation. Reduces capillary permeability due to histamine release. Inhibits fibroblast activity and collagen formation.

Inhibits the activity of phospholipase A2, which leads to suppression of prostaglandin and leukotriene synthesis. Inhibits the release of COX (mainly COX-2), which also helps to reduce the production of prostaglandins.

Reduces the number of circulating lymphocytes (T-and B-cells), monocytes, eosinophils and basophils due to their movement from the vascular bed to the lymphoid tissue; suppresses the formation of antibodies. Inhibits pituitary release of ACTH and beta-lipotropin, but does not reduce the level of circulating beta-endorphin. Inhibits TSH and FSH secretion.

Pharmacokinetics:  

When used systemically, it is mainly metabolized in the liver and partially in the kidneys. The main pathway of metabolism is 6-β-hydroxylation. It is excreted by the kidneys.

Indications

System application of Kenalog (in / m introduction): – hay fever; – chronic obstructive airway diseases (for example, bronchial asthma, chronic spastic bronchitis), with severe forms and negative results of local treatment;— skin diseases and contact dermatitis characterized by itching, flaking or blistering, such as contact dermatitis, pemphigoid, psoriasis, dermatitis herpetiformis, atopic, exfoliative and eczematoid dermatitis.

Contraindications

Hypersensitivity, gastric and duodenal ulcers, bone atrophy, mental illnesses (including in the anamnesis), viral diseases (herpetic pemphigus, shingles), chickenpox, amoebic and fungal infections, childhood polio (except for bulbar-encephalitis), glaucoma, age-from 12 to 16 years (iv use).

Side effects

Systemic — moon-shaped face, Cushing’s syndrome, adrenal atrophy, muscle weakness, bone and muscle atrophy, diabetes mellitus, menstrual disorders, impotence, increased hair growth, bleeding from the skin and mucous membranes, acne, potassium excretion, vasculitis, withdrawal syndrome, ulcerogenic effect, immune suppression, headaches, increased sweating, glaucoma, thrombosis.

Interaction

Systemic or repeated topical use should take into account interactions characteristic of systemic glucocorticoid therapy, which may weaken the hypoglycemic effect of antidiabetic drugs and the anticoagulant effect of coumarin derivatives.

When the drug is used simultaneously with cardiac glycosides, their action may intensify; when combined with saluretics, the release of potassium from the body may increase.

Concomitant use with NSAIDs or antirheumatic drugs may contribute to the development of gastrointestinal bleeding.

When taken concomitantly with rifampicin, the corticoid effect of Kenalog may be weakened.

How to take, course of use and dosage

Kenalog is administered intravenously, adults for systemic treatment-1 ml (40 mg) slowly, deeply, intraannually, up to 80 mg (repeated use after 4 weeks).

For intra-focal use (bursitis) in adults and children over 12 years of age – from 10 to 40 mg.

The interval between injections is at least 2 weeks.

When injected under the area of skin lesions,1 ml is diluted with a local anesthetic and 1 mg of the drug is administered per 1 cm 2 (no more than 30 mg per day in adults and 10 mg in children).

Repeated injection-after 2 weeks.

Overdose

Symptoms: Itsenko-Cushing syndrome, hyperglycemia, glucosuria.

Treatment: symptomatic with gradual withdrawal.

Special instructions

With systemic treatment with the drug, it is recommended to prescribe a diet enriched with proteins and vitamins.

For intraocular use in the treatment of tendons, inflammation of the tendon vagina and “tennis elbow”, it is recommended to use Kenalog 10 mg / ml.

With repeated use of the drug, the intervals between injections should be observed and, if necessary, the intervals between injections should be increased.

Form of production

Suspension for injection.

Storage conditions

In a dark place, at a temperature of 15-30 °C

Shelf life

3 years

Active ingredient

Triamcinolone

Conditions of release from pharmacies

By prescription

Dosage form

suspension for injection

Description

Adults as prescribed by a doctor

Indications

Allergy, Rheumatoid Arthritis, Dermatitis, Allergic Rhinitis, Osteoarthritis and Arthritis, Dermatosis, Bronchial Asthma, Bursitis, Insect Bites, Psoriasis